# Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis

> **NCT04867369** · PHASE4 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 160 (actual)

## Conditions studied

- Tendonitis

## Interventions

- **DRUG:** Bupivacaine 20mL 0.5%
- **DRUG:** Bupivacaine 20mL 0.25%
- **DRUG:** Bupivacaine up to 15mL 0.25%

## Key facts

- **NCT ID:** NCT04867369
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2023-11-08
- **Final completion:** 2023-11-11
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04867369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04867369, "Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04867369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*